Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609226 · ClinicalTrials.gov registry record · Phase 3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
A Phase 3 study of Sickle Cell Disease and Thalassemia, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT06609226 is a Phase 3 study of Sickle Cell Disease and Thalassemia that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 480 participants, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06609226, a Phase 3 study of Sickle Cell Disease and Thalassemia, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.
Conditions Studied
Interventions
- DRUG Etavopivat A
- DRUG Etavopivat B
- DRUG Etavopivat C
Study Locations (20)
California
- Children's Hospital Los Angeles - Endocrinology - Los Angeles
- Children's Hospital Los Angeles - Endocrinology - Los Angeles
- UCSF Oakland Benioff ChildHosp - Oakland
- UCSF Oakland Benioff ChildHosp - Oakland
- Children's Hosp Of Orange - Orange
- University Of California Irvine - Orange
Georgia
- Emory University School of Medicine - Atlanta
- Children's Healthcare Atlanta - Atlanta
- Center for Blood Disorders Augusta University - Augusta
Florida
- Foundation for Sickle Cell Disease Research - Hollywood
- Univ of Miami/SCCC - Miami
Alabama
- Univ of Alabama Birmingham - Birmingham
Arizona
- Phoenix Children's Hsptl - Phoenix
Connecticut
- University of Connecticut - Farmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Univer Of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2030-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06609226
The ClinicalTrials.gov registry entry for NCT06609226 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (65% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Etavopivat A is the first listed.
NCT06609226 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Georgia, Florida.
Frequently Asked Questions
What is clinical trial NCT06609226 about?
NCT06609226 is a clinical study titled "A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia". Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking in...
What is the current status of trial NCT06609226?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-01-10. Estimated completion is 2030-12-30.
What conditions does trial NCT06609226 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Thalassemia.
What interventions are being tested in trial NCT06609226?
The interventions under investigation include: Etavopivat A (DRUG), Etavopivat B (DRUG), Etavopivat C (DRUG).
Who is sponsoring clinical trial NCT06609226?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06609226 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RECRUITING · Phase 3
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
RECRUITING · Phase 3
-
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
RECRUITING · Phase 3
-
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
-
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.